{"filings":[{"id":1639476,"accession_number":"0001193125-26-303393","cik":2093101,"company_name":"Atrium Therapeutics, Inc.","ticker":"RNA","form_type":"8-K","filed_at":"2026-07-14T21:14:28+00:00","items":["8.01","9.01"],"status":"ready","headline":"Atrium Therapeutics receives FDA IND clearance for ATR 1072 in PRKAG2 syndrome; Phase 1/2 trial to start","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA cleared IND for ATR 1072, a precision cardiology RNA therapeutic for PRKAG2 syndrome.","Corventis Phase 1/2 trial will enroll ~37 participants; first patient expected by end of 2026.","Initial proof-of-concept data anticipated in second half of 2027.","PRKAG2 syndrome is a rare genetic cardiomyopathy with no approved therapy addressing root cause.","This is Atrium's first precision cardiology program to enter clinic."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":239906633.36538464,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":"2026-07-14","daily_digest_url":"/daily/2026-07-14","daily_digest_rank":5},{"id":444276,"accession_number":"0001193125-26-224238","cik":2093101,"company_name":"Atrium Therapeutics, Inc.","ticker":"RNA","form_type":"8-K","filed_at":"2026-05-14T20:50:07+00:00","items":["2.02","9.01"],"status":"ready","headline":"Atrium Therapeutics reports Q1 collaboration revenue $19.6M, driven by $15M BMS milestone; cash $267.8M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Collaboration revenue $19.6M in Q1 2026, primarily a $15M milestone from BMS partnership.","R&D expenses $16.7M, G&A $20.3M; cash and equivalents $267.8M.","ATR 1072 IND submission planned for H2 2026; pre-IND discussions with FDA/Health Canada completed.","Company launched as independent public on Feb 27, 2026 after spin-off from Avidity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":239906633.36538464,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":112737,"accession_number":"0001193125-26-083227","cik":2093101,"company_name":"Atrium Therapeutics, Inc.","ticker":"RNA","form_type":"8-K","filed_at":"2026-02-27T23:59:59+00:00","items":["1.01","5.01","5.02","9.01"],"status":"ready","headline":"Atrium Therapeutics completes spin-off from Avidity; begins trading under RNA on Nasdaq","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Separation of Atrium Therapeutics (SpinCo) from Avidity effective Feb 26, 2026; one SpinCo share for every ten Avidity shares distributed.","Amended License Agreement expands IP cross-licenses; Transition Services Agreement provides support services from Avidity.","Board elected: Carsten Boess, W. Michael Flanagan, Simona Skerjanec, Troy Wilson; terms expire at first/second annual meetings.","Executive officers: Kathleen Gallagher (CEO) and Brendan Winslow (CFO); employment agreements and compensatory plans adopted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":239906633.36538464,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":112736,"accession_number":"0001193125-26-077105","cik":2093101,"company_name":"Atrium Therapeutics, Inc.","ticker":"RNA","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Atrium Therapeutics completes spin-off from Avidity; 15.5M shares distributed, trading begins Feb 27 under RNA","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Avidity distributed 15,514,966 Atrium shares at a ratio of 1 share per 10 Avidity shares; holds no equity interest after.","Atrium shares expected to begin trading on Nasdaq under symbol RNA on February 27, 2026.","Registration statement declared effective and spin-off consummated on February 26, 2026.","Novartis acquisition of Avidity expected to close on February 27, 2026, subject to conditions.","Atrium focused on early-stage precision cardiology programs ATR-1086 (phospholamban) and ATR-1072 (PRKAG2 syndrome)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":239906633.36538464,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}